Side effects, cost, supply, target: four reasons with four trajectories
Why the reason for stopping changes what happens afterwards.
TheCompound Journal
Reporting on incretins, compounding & the peptide supply chain
Reconstitution
The graduation interval differs between barrel sizes, and a 1 mL barrel is frequently marked in two-unit steps. Reading one as though it were marked in single units halves or doubles a dose.
There is a detail on the barrel that causes more trouble than the convention itself. Small insulin syringes — the 0.3 mL and 0.5 mL barrels — are generally marked in single-unit increments, and some 0.3 mL barrels in half units. The 1 mL barrel is very often marked in two-unit increments, because a hundred single marks will not fit legibly. A person who learns to count marks on one barrel and then buys another size will count the same marks and administer twice or half what they intend. We have seen this reported repeatedly, and it is invisible unless somebody looks at the printing.
An insulin syringe is graduated in units on a convention that fixes one hundred units to one millilitre. A unit is therefore ten microlitres of liquid. That is the entire definition and it contains no information about drug content.
The convention works for insulin because insulin is supplied at a standardised strength: U-100 insulin contains one hundred international units of insulin activity per millilitre, so one syringe unit delivers one insulin unit. The volumetric mark and the dose mark coincide, which is why generations of patients have been able to dose by counting marks without ever thinking about volume.
Take the same syringe and use it for a peptide reconstituted at a concentration of the user’s choosing and the coincidence breaks. The syringe is still an accurate volumetric instrument; it is simply no longer a dosing instrument. Everything a person needs in order to convert marks into micrograms depends on a calculation somebody has to perform.
The Journal labours this because it is the root of the largest errors in this market. A reader who takes away only one sentence should take away this one: the unit tells you the volume, and only the concentration tells you the dose.
U-100 insulin syringes are commonly supplied in three barrel sizes. The 0.3 mL barrel holds thirty units and is usually graduated in single units, with some products marked in half units. The 0.5 mL barrel holds fifty units and is generally marked in single units. The 1 mL barrel holds one hundred units and is very often marked in two-unit increments, because a hundred legible single marks will not fit on a barrel of that length.
The practical consequence is direct. A person accustomed to counting single marks on a 0.5 mL barrel who switches to a 1 mL barrel and counts the same number of marks will draw twice the intended volume. The reverse switch halves it. Nothing about the appearance of the syringe warns of this; only the printed numerals do, and they are small.
The general rule that follows is to choose the smallest barrel that comfortably holds the intended volume, both for graduation resolution and because a small volume measured near the bottom of a large barrel is the least accurate configuration available. Where a dose is genuinely small — a few units — a half-unit-graduated 0.3 mL barrel is the only presentation that offers meaningful resolution.
Skin is about two millimetres thick and barely varies with body size. That one measurement is why long needles lost the argument.
On needle lengthThree reading errors recur. The first is counting marks rather than reading numerals, which fails at the first change of barrel size. The second is reading to the wrong part of the plunger: the measurement is taken at the leading edge of the rubber stopper, not the tip of any conical projection beyond it, and on some designs the difference is a full unit. The third is parallax, which sounds fussy and is not: at small volumes, viewing the barrel from above or below the mark introduces a readable error.
The remedy for all three is the same and takes seconds. Read the numeral, not the count. Hold the barrel at eye level. Identify the leading edge of the stopper before drawing rather than after.
There is a further consideration specific to this market. Syringes sold for general medical use — tuberculin syringes, for instance — are graduated in millilitres and fractions of a millilitre. They are the same size and shape as insulin syringes, and in the same drawer. Using them requires reading a completely different scale, and the failure to notice the substitution is the single commonest route to a tenfold error that we have documented.
| Site | Approx. skin thickness | Adequate needle | Risk with 12.7 mm |
|---|---|---|---|
| Abdomen | ≈2.2 mm | 4 mm | Low to moderate |
| Thigh (anterior/lateral) | ≈1.9 mm | 4 mm | Intramuscular in lean limbs |
| Upper arm (posterolateral) | ≈2.2 mm | 4 mm | Intramuscular in lean arms |
| Upper outer buttock | ≈2.4 mm | 4 mm | Low |
| Skin thickness figures are approximate population means from ultrasound studies and vary little with body mass index. Subcutaneous fat thickness varies greatly, which is why the risk column does. | |||
Dead space is the volume held in the needle and hub after the plunger has bottomed out. For a fixed-needle insulin syringe it is very small, of the order of two to seven microlitres. For a detachable needle on a conventional luer fitting it is considerably larger, sometimes exceeding fifty microlitres.
Whether that matters is a question of proportion. At an intended volume of two hundred microlitres, a five-microlitre loss is under three per cent and irrelevant. At an intended volume of twenty microlitres — which a concentrated reconstitution produces — the same loss is a quarter of the dose. This is one of the strongest practical arguments against making a vial up to a very high concentration: it pushes the injection volume down into the range where fixed losses dominate.
Air bubbles interact with the same arithmetic. A bubble displaces solution, so a barrel drawn to eight units containing a one-unit bubble delivers seven units of drug. Small bubbles in a subcutaneous injection are not a safety problem in the way they would be intravenously; they are a dosing problem. Expelling them by tapping the barrel upright and pushing the plunger to the mark is a volumetric correction, not a ritual, and it matters most at exactly the small volumes where people are least inclined to bother.
Unit (U-100): ten microlitres. A volume, not an amount of drug. Concentration: mass per volume, here usually milligrams per millilitre. Dead space: volume retained in needle and hub after full depression of the plunger. Priming: expelling a small volume before dosing, to clear air and confirm flow.
Gauge: needle bore, inversely numbered — higher gauge is thinner. Subcutaneous: into the fat layer beneath the dermis. Intradermal: within the skin itself, which is what an oblique short needle risks. Intramuscular: into muscle beneath the subcutaneous layer.
Lipohypertrophy: thickened subcutaneous tissue from repeated injection, with blunted and variable absorption. Lipoatrophy: localised loss of subcutaneous fat, a different and now rare immune-mediated phenomenon. Bacteriostatic: inhibiting microbial growth, not sterilising. In-use period: the interval after first puncture during which a product remains within specification, established by stability testing.
The distinction between bacteriostatic and sterile, and the distinction between purity and content, account between them for a large share of the confused correspondence this desk receives.
One thing we would like to see changed is trivially achievable. Needles are cheap, and reuse is driven almost entirely by cost and availability rather than by any belief that it is safe. Of every technique failure catalogued above, that is the one most responsive to supply, and the one where the barrier is commercial rather than educational.
Selected from correspondence received on this article. Writers are identified by initial, surname and city, verified before printing. Replies are from the desk that filed the piece or from the standards editor. Write to letters@compoundjournal.com.
Nothing in this file addresses what to do when you realise mid-week that you have made an error. I gave double my dose on a Sunday and could find no guidance anywhere about what that meant.
— J. Vasilenko, Chisinau
A real gap and we will address it properly rather than in a reply. The short version is that it is a pharmacokinetic question — how much excess exposure, over what half-life — and a clinical one about symptom burden, and neither is answerable in the abstract. It also belongs in the titration file, which currently discusses omission and not excess.
I gave myself a tenth of my intended dose for five weeks. I had been using insulin syringes, ran out, and used the 1 mL syringes that came with the vials, which are marked in millilitres. I did not notice because the plunger was in roughly the same place. Nobody warned me these were different scales.
— K. Sivertsen, Bergen
This is the error we rank first for magnitude and we are grateful for the account, because it happened exactly as the mechanism predicts: a substitution that produced no visible signal. The one structural defence is to buy syringes deliberately and keep to a single type rather than using whatever arrives in the parcel.
Your needle-length section says four millimetres is adequate for all adults, which contradicts what I was told by a nurse who insisted on half an inch because of my weight. Which is right?
— S. Bergqvist, Malmö
The published recommendations are with us, and the reason is that skin thickness varies remarkably little with body mass while subcutaneous fat varies enormously. A longer needle in a heavier person is not more likely to reach the right layer; it is only more likely to go past it in a thinner limb. We would put the ultrasound measurement studies in front of your nurse rather than argue from authority.
Why the reason for stopping changes what happens afterwards.
We have catalogued what readers report, ranked by the size of the dosing error each produces.
Cost is the modal reason for discontinuation in every dataset we have seen, and it is absent from the clinical literature.
The evidence base is thin and the document says so, which is to its credit.
An effect is dose-limiting when it prevents adequate intake, prevents normal activity, or produces a risk of its own. Discomfort alone is not the test.
The evidence base is thin and the document says so, which is to its credit.